Brian F. Chapin, MD

Brian F. Chapin, MD, is Director of Clinical Research and Associate Professor at The University of Texas MD Anderson Cancer Center. His research focuses on prostate cancer, specifically metastatic and oligometastatic disease, neoadjuvant androgen receptor pathway inhibitor combinations, and PSMA-PET imaging for lymph node staging and recurrence detection. He leads the phase 2 EXTEND trial evaluating metastasis-directed therapy with continuous androgen deprivation, and the GUNS neoadjuvant genomic umbrella study correlating genomic alterations with pathologic responses. His recent work includes the LIGHTHOUSE post-hoc analysis of ¹⁸F-flotufolastat PET/CT and NCCN guideline authorship. He has published in European Urology, Journal of Clinical Oncology, and The Journal of Urology.